Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sivan Gazit

Showing results (21-30 of 73) with videos related to

Pageof 8
Sort By:
JAMA Network Open|April 4, 2025
Early-Life Exposure to Acid-Suppressive Therapy and the Development of Celiac Disease AutoimmunityTomer Achler, Tal Patalon, Sivan Gazit, et al.
Scientific Reports|March 24, 2026
Analyzing the digital customer journey: a novel framework for sequential behavior modelingLihi Bar-El, Hila Chalutz-BenGal, Sivan Gazit, et al.
BMJ (Clinical Research Ed.)|May 24, 2022
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control studySivan Gazit, Yaki Saciuk, Galit Perez, et al.
The Lancet. Respiratory Medicine|November 21, 2022
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort studyMatan Yechezkel, Merav Mofaz, Amichai Painsky, et al.
Nature Communications|June 10, 2022
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccineTal Patalon, Yaki Saciuk, Asaf Peretz, et al.
Inflammatory Bowel Diseases|July 24, 2024
The Prevalence and Characteristics of Inflammatory Bowel Disease-related Ocular Involvement in ChildrenAmir Ben-Tov, Tomer Achler, Tal Patalon, et al.
JAMA Network Open|June 7, 2021
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After ImmunizationGabriel Chodick, Lilac Tene, Tal Patalon, et al.
JAMA Internal Medicine|November 30, 2021
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA VaccineTal Patalon, Sivan Gazit, Virginia E Pitzer, et al.
The Lancet. Digital Health|February 7, 2026
Smartwatch-derived versus self-reported outcomes of physiological recovery after COVID-19, influenza, and group A streptococcus: a 2-year prospective cohort studyYosi Levi, Varun Gande, Erez Shmueli, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 24, 2024
Strength in Numbers: Identifying a Significant Association between High Serum Ferritin Levels and Newly Diagnosed Malignancy in a Large Health Organization CohortAlon Simchovitz Gesher, Keren Grinin, Dor Atias, et al.
Pageof 8

Showing results (21-30 of 73) with videos related to

Sort By:
Pageof 8
JAMA Network Open|April 4, 2025
Early-Life Exposure to Acid-Suppressive Therapy and the Development of Celiac Disease AutoimmunityTomer Achler, Tal Patalon, Sivan Gazit, et al.
Scientific Reports|March 24, 2026
Analyzing the digital customer journey: a novel framework for sequential behavior modelingLihi Bar-El, Hila Chalutz-BenGal, Sivan Gazit, et al.
BMJ (Clinical Research Ed.)|May 24, 2022
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control studySivan Gazit, Yaki Saciuk, Galit Perez, et al.
The Lancet. Respiratory Medicine|November 21, 2022
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort studyMatan Yechezkel, Merav Mofaz, Amichai Painsky, et al.
Nature Communications|June 10, 2022
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccineTal Patalon, Yaki Saciuk, Asaf Peretz, et al.
Inflammatory Bowel Diseases|July 24, 2024
The Prevalence and Characteristics of Inflammatory Bowel Disease-related Ocular Involvement in ChildrenAmir Ben-Tov, Tomer Achler, Tal Patalon, et al.
JAMA Network Open|June 7, 2021
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After ImmunizationGabriel Chodick, Lilac Tene, Tal Patalon, et al.
JAMA Internal Medicine|November 30, 2021
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA VaccineTal Patalon, Sivan Gazit, Virginia E Pitzer, et al.
The Lancet. Digital Health|February 7, 2026
Smartwatch-derived versus self-reported outcomes of physiological recovery after COVID-19, influenza, and group A streptococcus: a 2-year prospective cohort studyYosi Levi, Varun Gande, Erez Shmueli, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 24, 2024
Strength in Numbers: Identifying a Significant Association between High Serum Ferritin Levels and Newly Diagnosed Malignancy in a Large Health Organization CohortAlon Simchovitz Gesher, Keren Grinin, Dor Atias, et al.
Pageof 8